TrialEuropean heart journal2017

Low-density lipoprotein cholesterol targeting with pitavastatin + ezetimibe for patients with acute coronary syndrome and dyslipidaemia: the HIJ-PROPER study, a prospective, open-label, randomized trial.

Nobuhisa Hagiwara et al.PubMed ↗Full text ↗Publisher ↗

Pitavastatin plus ezetimibeno clear effectNo clear effect on primary endpoint.Nothing cleared the noise.
Statin plus ezetimibelooks good hereLower primary endpoint.Correlation only, not a test of it.

What the trial testedas reported · 1,734 people · 2017

Range includes no effect

No clear effect on primary endpoint

−11%−24% to +4%

pitavastatin plus ezetimibe vs pitavastatin monotherapy

Bigger than 2 in 10 on the map

As reported

HR 0.89, 95% CI 0.76–1.04

What moved togetherboth groups pooled, not the treatment’s effect

Correlation, not cause

Statin plus ezetimibe went with lower primary endpoint

−29%−44% to −9%

statin plus ezetimibe vs statin monotherapy, in ACS patients with higher cholesterol absorption, represented by elevated pre-treatment sitosterol

Bigger than 6 in 10 on the map

As reported

HR 0.71, 95% CI 0.56–0.91

Who was studied, and how

1,734people with cardiovascular disease, in this paper

The trial randomly assignedassigned by chance

pitavastatin plus ezetimibe

pitavastatin monotherapy

No clear effect on primary endpoint−11%

randomised

Already taking statin plus ezetimibe, or nottheir own situation, not assigned

on statin plus ezetimibe

statin monotherapy

Statin plus ezetimibe went with lower primary endpoint−29%

correlation, not a test

the abstract, start to end

… (283/864, 32.8% vs. 316/857, 36.9%; HR 0.89, 95% CI 0.76-1.04, P = 0.152).

… in the statin plus ezetimibe group (HR 0.71, 95% CI 0.56-0.91).

← favours treatmentfavours comparator →

could be chance

Primary endpointpitavastatin plus ezetimibe vs pitavastatin monotherapy

HR 0.890.76–1.04

Primary endpointstatin plus ezetimibe vs statin monotherapy, in ACS patients with higher cholesterol absorption, represented by elevated pre-treatment sitosterol

HR 0.710.56–0.91

StatinsOther lipid agentsLipids

1 / 4

45 papers cite it

2017

2018

2019

2020

2021

2022

2023

2024

2025

2026

this paperpooled ittrialcites it